We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.115 | -3.32% | 3.35 | 3.20 | 3.35 | 3.45 | 3.30 | 3.45 | 1,849,184 | 15:40:43 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | 0 | -2.92M | -0.0070 | -4.71 | 14.43M |
From Mar 2023 to Mar 2025
By Kyle Morris
Shares in ImmuPharma PLC rose 9.4% on Monday after the company said it has submitted a Phase 2/3 clinical trial protocol to the U.S. Food and Drug Administration for its Lupuzor candidate for Lupus patients.
The company said the new trial design takes into account FDA guidance from a previous meeting, and that the Phase 2/3 study remains on track to commence in the second half.
"We are extremely pleased to be moving positively forward with the Lupuzor(TM) program. Avion and ourselves believe that the new design of the Phase 2/3 adaptive study offers the greatest probability of a successful result for the overall benefit of Lupus patients. We remain on track to commence the trial in H2 2023," Chief Executive Tim McCarthy said.
Shares at 0738 GMT were up 0.17 pence at 2.00 pence.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
March 27, 2023 04:08 ET (08:08 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Immupharma Chart |
1 Month Immupharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
